2023 GOLD COPD Update
The latest COPD guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), has updated its guideline synopses for COPD diagnosis, initial maintenance, treatment, and Exacerbation.
Please refer to the full statement for the unabbreviated guidelines. https://goldcopd.org/
Some of the many Key changes:
- A new classification of COPD exacerbation severity was added.
- The ABCD tool was replaced with the new GOLD ABE Assessment tool, recognizing the clinical independent relevance of exacerbations.
- An “Exacerbation” is now defined as “increased dyspnea and/or cough and sputum production that worsens over a period of <14 days.”
- Combination LABA+LAMA is recommended up front for patients with more persistent/severe symptoms (Group B).
- Triple treatment (LABA+LAMA+ICS) is recommended in preference to LABA+ICS for patients with more severe symptoms and higher exacerbation risk (Group E).
- Blood eosinophil levels are emphasized as a biomarker to guide treatment decisions.
- A new classification of COPD exacerbation severity was added.
- The ABCD tool was replaced with the new GOLD ABE Assessment tool, recognizing the clinical independent relevance of exacerbations.
- An “Exacerbation” is now defined as “increased dyspnea and/or cough and sputum production that worsens over a period of <14 days.”
- Combination LABA+LAMA is recommended up front for patients with more persistent/severe symptoms (Group B).
- Triple treatment (LABA+LAMA+ICS) is recommended in preference to LABA+ICS for patients with more severe symptoms and higher exacerbation risk (Group E).
- Blood eosinophil levels are emphasized as a biomarker to guide treatment decisions.
